We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Allied Corp (QB) | USOTC:ALID | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.052 | 0.051 | 0.067 | 0.00 | 13:30:22 |
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 29, 2019 (September 10, 2019)
Allied Corp. |
(Exact Name of Registrant as Specified in its Charter) |
Nevada |
|
0-27675 |
|
33-1227173 |
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
1405 St. Paul St., Suite 201, Kelowna, BC Canada |
|
V1Y 9N2 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (877) 255-4337
Cosmo Ventures, Inc., 112 North Curry Street, Carson City, Nevada 89703 |
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Explanatory Note.
Allied Corp. (“Company”) is hereby amending its Form 8-K filed on September 10, 2019, to include the financial statements for AM (Advanced Micro) Biosciences, Inc. as of August 31, 2019 and the related statements of operations and comprehensive loss, stockholders’ equity and cash flows for the period from incorporation on September 13, 2018 to August 31, 2019. As previously announced on Form 8-K filed on November 15, 2019, the Company has changed its fiscal year end to August 31. Starting with the periodic report for the quarter ended November 30, 2019, the Company will file annual and quarterly reports based on August 31 fiscal year.
Section 9 – Financial Statements and Exhibits
Item 9.01(a) Financial Statements and Exhibits
Balance Sheet of AM (Advanced Micro) Biosciences Inc. as of August 31, 2019, and the related statements of operations and comprehensive loss, stockholders’ equity and cash flows for the period from incorporation on September 13, 2018 to August 31, 2019.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
|
2 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this amendment to report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
|
Allied Corp. |
|
|
(Registrant) |
|||
Dated: November 29, 2019 | By: | /s/ Calum Hughes | |
|
|
Chief Executive Officer |
|
3 |
1 Year Allied (QB) Chart |
1 Month Allied (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions